Modulation of autoantibody production by mycophenolate mofetil: effects on the development of SLE in (NZBxNZW)F1 mice
- 1 May 2003
- journal article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 18 (5) , 878-883
- https://doi.org/10.1093/ndt/gfg034
Abstract
Background. Mycophenolate mofetil (MMF) has been successfully used to improve or prevent the development of systemic lupus erythematosus (SLE) in both humans and in several lupus‐prone mice. In the present study, we evaluated mechanisms through which MMF may exert its therapeutic effect on the development of systemic autoimmunity.Keywords
This publication has 17 references indexed in Scilit:
- IgG Fc ReceptorsAnnual Review of Immunology, 2001
- MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTSTransplantation, 1997
- Interleukin-4 Protects against a Genetically Linked Lupus-like Autoimmune SyndromeThe Journal of Experimental Medicine, 1997
- Immunoglobulin G–mediated Inflammatory Responses Develop Normally in Complement-deficient MiceThe Journal of Experimental Medicine, 1996
- Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice.Journal of Clinical Investigation, 1996
- An MRL/MpJ-lpr/lpr substrain with a limited expansion of lpr double-negative T cells and a reduced autoimmune syndromeInternational Immunology, 1993
- Towards a comprehensive view of immunoglobulin class switchingImmunology Today, 1993
- In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon.The Journal of Experimental Medicine, 1987
- Activation of mouse complement by monoclonal mouse antibodiesEuropean Journal of Immunology, 1981
- Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and CyclophosphamideNew England Journal of Medicine, 1978